Latest News

Oslo, Norway, July 13, 2021: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces highlights from a successful European Association of Urology virtual congress, continuing the steady flow of new scientific data being presented on the importance of Blue Light Cystoscopy (BLC^®) in Bladder Cancer management.

Oslo, Norway, 7 July 2021: Photocure ASA (OSE: PHO), calls for an extraordinary general meeting of Photocure to be held in Advokatfirmaet Selmer AS' premises in Tjuvholmen allé 1, 0252 Oslo on 28 July 2021 at 17:00 hours (CEST).

Oslo, Norway, 7 July 2021: Photocure ASA (OSE: PHO), calls for an extraordinary general meeting of Photocure to be held in Advokatfirmaet Selmer AS' premises in Tjuvholmen allé 1, 0252 Oslo on 28 July 2021 at 17:00 hours (CEST).

Press Release – Oslo, Norway, 23 June, 2021: Photocure, The Bladder Cancer Company, announces the publication of a study in the journal Urologic Oncology. The study objective was to determine the estimated budget impact to practices that incorporate blue light cystoscopy (BLC^®) with hexaminolevulinate HCl (HAL) for the surveillance of non-muscle-invasive bladder cancer (NMIBC) in the clinic setting.

Oslo, Norway, 22 June, 2021: Photocure ASA (OSE:PHO) today announces that its partner Asieris Pharmaceuticals (Asieris) has administered the first European patient in its phase III clinical trial for APL-1702 (Cevira^®).

Oslo, Norway, 14 June 2021: Reference is made to the stock exchange release by Photocure ASA ("Photocure" or the "Company") published on 7 June 2021 regarding a share capital increase following the exercise of share options.

Oslo, Norway, 8 June 2020: Reference is made to the stock exchange release by Photocure ASA ("Photocure" or the "Company") published on 7 June 2021 regarding initiation of a share buyback program.

Oslo, Norway, 9 June 2021: Reference is made to the stock exchange release by Photocure ASA ("Photocure" or the "Company") published on 7 June 2021 regarding exercise of share options.

Oslo, Norway, 7 June 2021: Participants in Photocure ASA's ("Photocure" or the "Company") share option program have on 7 June 2021 exercised a total of 98,251 options distributed as follows:

• 9,501 options exercised according to the option program for 2017 at a strike price of NOK 38.06; and
• 88,750 options exercised according to the option program for 2019 at a strike price of NOK 50.72

Oslo, Norway, June 7, 2021

Photocure ASA ("Photocure" or the "Company") has decided to initiate a buyback of up to 50,000 of its own shares for a total maximum amount of NOK 12,500,000. The buyback program may be carried out in the period from this announcement and until June 30, 2021.

Press Release – Oslo, Norway, 27 May 2021, Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces that President and Chief Executive Officer, Daniel Schneider and Chief Financial Officer, Erik Dahl are scheduled to present corporate overviews at two upcoming institutional investor conferences in June.

Oslo, Norway, 20 May 2021: Photocure ASA (OSE: PHO), held its annual general meeting on 20 May 2021 at 17:00 hours (CET).

Oslo, Norway, 19 May 2021: Reference is made to the stock exchange release by Photocure ASA ("Photocure" or the "Company") (OSE: PHO) published on 15 September 2021 regarding 370,000 share options granted conditionally.

Oslo, Norway, 19 May 2021: Photocure ASA (OSE:PHO), the Bladder Cancer Company, today reported Hexvix^®/Cysview^® revenues of NOK 81.6 million in the first quarter of 2021 (Q1 2020: NOK 54.4 million), and EBITDA of NOK 18.1 million (NOK -4.8 million), following the continued successful launch in markets previously operated by Ipsen Pharma SAS. The third Covid-19 wave impacted operations in the quarter, but a strong March performance indicates the environment is improving.

Oslo, Norway, May 18, 2021: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that notification was given to its partner and exclusive distributor, Genotests SpA by the Instituto de Salud Pública de Chile that the Marketing Authorization Application (“MAA”) for Hexvix^® has been accepted for regulatory review.

Oslo, Norway, 14 May 2021: Photocure ASA (OSE:PHO) - the Annual General Meeting (AGM) at will be held 20 May 17:00 CEST. The AGM will be live streamed and Dan Schneider, President & Chief Executive Officer, will provide a general company update.

Oslo, Norway, 13 May 2021: Photocure ASA (Photocure, PHO: OSE) will announce the first quarter 2021 financial results on Wednesday 19 May 2021 at 07:00 CET and invites investors, analysts and the media to a presentation at 14:00 CET the same day.